Drug Profile
YP 001
Alternative Names: Sabarep; Skin protease inhibitor YP001 - York Pharma; YP-001Latest Information Update: 04 Apr 2011
Price :
$50
*
At a glance
- Originator York Pharma
- Class Skin disorder therapies
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atopic dermatitis; Contact dermatitis
Most Recent Events
- 13 Dec 2005 Phase-II clinical trials in Atopic dermatitis in United Kingdom (Topical)
- 13 Dec 2005 Phase-II clinical trials in Contact dermatitis in United Kingdom (Topical)
- 13 Sep 2005 Phase-I clinical trials in Atopic dermatitis in United Kingdom (Topical)